Report on HIV/AIDS drug access shows 'encouraging, painfully slow progress,' editorial says

NewsGuard 100/100 Score

A recent report released by UNAIDS, UNICEF and the World Health Organization on antiretroviral drug access "reported encouraging but painfully slow progress in 2007, the good news tempered by grave challenges," an Akron Beacon Journal editorial says.

The report found that although the rate of HIV/AIDS-related deaths "continues to decline," almost "2.5 million new infections were recorded last year," the editorial says, adding that the 3 by 5 Initiative target" has been met, but two years after the target date." In addition, "HIV testing and counseling have increased significantly in many countries," but "surveys suggest the majority of [HIV-positive] people are unaware of their status," according to the editorial. It adds that between 2004 and 2007, the "cost of most antiretroviral therapies in poor countries dropped 30% to 64%" but that "as patients live longer, the funding must rise as well, an estimated $41 billion required by 2015 to meet the needs."

HIV/AIDS "need not be the inevitable sentence of death it was some 20 years ago," the editorial says, adding, "Among the important contributors to the extended survival rate is increased access to cheap antiretroviral drug treatments." To provide all of the estimated 33.2 million people living with HIV/AIDS worldwide with drug access "early enough is an enormous task that demands an enduring commitment," the editorial concludes (Akron Beacon Journal, 6/4).


Kaiser Health NewsThis article was reprinted from khn.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Common HIV drugs linked to reduced Alzheimer's disease risk